GlassScriptPhysician profile
Gary G Shi
NPI 1235101437
$15,939.54
in general payments reported to CMS, 2019-2025
39 companies · $409 in 2025
The $409 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $81.72 · 2021: $491 · 2022: $893 · 2023: $12K · 2024: $807 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,300 · Food and Beverage: $1,566 · Travel and Lodging: $1,053 · Education: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,300.00 |
| Food and Beverage | $1,565.69 |
| Travel and Lodging | $1,053.36 |
| Education | $952.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $10,698.27 | 2023 | |
| Astellas Pharma US INC | $543.12 | 2019-2025 | Xtandi, Vyloy, Padcev |
| E.R. Squibb & Sons, L.L.C. | $481.95 | 2019-2025 | Opdivo |
| Lilly USA, LLC | $420.70 | 2024 | Verzenio, Jaypirca |
| Genentech USA, INC. | $398.03 | 2019-2025 | Perjeta, Venclexta, Tecentriq |
| Janssen Biotech, INC. | $347.63 | 2019-2022 | |
| Pfizer INC. | $323.91 | 2019-2025 | |
| Seagen INC. | $305.94 | 2019-2023 | |
| Amgen INC. | $252.01 | 2019-2023 | Kyprolis |
| Astrazeneca Pharmaceuticals LP | $243.61 | 2019-2023 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $229.85 | 2019-2024 | |
| Incyte Corporation | $224.53 | 2023-2024 | Jakafi |
| Genzyme Corporation | $174.19 | 2019-2023 | |
| Celgene Corporation | $162.56 | 2019-2025 | Pomalyst, Reblozyl |
| Merck Sharp & Dohme LLC | $130.18 | 2019-2023 | Keytruda, Lynparza |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Shi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.